In this segment of The Motley Fool's everything-financials show,�Where the Money Is, banking analysts Matt Koppenheffer and David Hanson place a bet on which bank stock, Wells Fargo or JPMorgan Chase, will outperform after releasing its second-quarter earnings on Friday morning.
While the bet is short-term in nature, Matt and David view the reasons behind their picks as long term trends.
Will tomorrow's reports drive the market higher?
Banks are set to begin reporting second-quarter earnings over the next few weeks. Many investors are terrified about investing in big banking stocks after the crash, but the sector has one notable stand-out. In a sea of mismanaged and dangerous peers, it rises above as "The Only Big Bank Built to Last." You can uncover the top pick that Warren Buffett loves in The Motley Fool's�new report. It's free, so�click here to access it now.
To follow The Fool's coverage of financial stocks,�click here!
Top 10 US Stocks To Invest In 2015: AEterna Zentaris Inc.(AEZS)
Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. Its lead oncology compounds include perifosine, a PI3K/Akt pathway inhibitor that is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, endometrial, castration refractory prostate, and refractory bladder cancer. The company?s lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for adult growth hormone deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.
Advisors' Opinion:- [By Sean Williams]
What's coming down the pipeline
Avastin: Surprise: It's Roche's (NASDAQOTH: RHHBY ) wonder drug yet again! Roche's Avastin is in the process of being tested as a treatment for recurrent endometrial cancer and demonstrated promising results in a mid-stage trial according to the Journal of Clinical Oncology. Avastin, which is an angiogenesis inhibitor (a fancy way of saying it inhibits blood vessel growth), was tested on 52 evaluable patients and delivered a progression-free survival of at least six months for 21 of them. Overall median PFS was 4.2 months, and median overall survival came in at 10.5 months. Don't be surprised if Roche decides to pursue further studies of Avastin in recurrent endometrial cancer with these results.� AEZS-108: Currently in late-stage development by Aeterna Zentaris (NASDAQ: AEZS ) , a holding in my own portfolio, AEZS-108 is an intravenous treatment composed of a synthetic peptide carrier and doxorubicin that targets Luteinizing Hormone Releasing Hormone-receptor expressing tumors. That series of scientific jargon simply means it targets cancer cells with minimal healthy cell death relative to the current standards of treatment. In mid-stage trials, AEZS-108 delivered an overall response rate of 30.8% and a clinical benefit rate of 74.4%. These figures were enough to get AEZS-108 a special protocol assessment (SPA), which should streamline its approval if these results stay consistent in late-stage studies.
As we saw with the current treatment options, the endometrial cancer pipeline isn't filled with a lot of choices, but they are at least more encouraging than the standard care treatments we've seen over the past three decades.Your best investment
With very few investable options to choose from, since many of these treatments are off patent as they're decades old, I'm going to split my decision this week between Roche and Aeterna Zentaris for obvious reasons. - [By Sean Williams]
High-risk, high-reward suggestions
Exelixis (NASDAQ: EXEL ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN ) : In February, Roche�and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to
There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on.
Best Stocks To Own Right Now: MeetMe Inc (MEET)
MeetMe, Inc. (MeetMe), incorporated on April 17, 2011, is a social network for meeting new people in the United States and the public market for social discovery. MeetMe makes meeting new people fun through social games and apps, monetized by both advertising and virtual currency. The Company has 60% customers coming from mobile. MeetMe is the social gathering place for the mobile generation. The Company operates MeetMe.com and MeetMe apps on iPhone, iPad, and android in English, Spanish and Portuguese.
The Company provides advertising facilities through MeetMe Ads and Social Theater. MeetMe Ads had over two billion page views monthly, over 78 million registered users across the world and approximately 50% of activity on mobile, as of November 17, 2012. Social Theater consists of traditional marketing and social networking.
Advisors' Opinion:- [By Rich Bieglmeier]
Harper say of his new idea, "We are initiating coverage of social networking platform MeetMe, Inc. (MEET) with a Buy rating and a $4.50 price target. We expect the company to increase the number of mobile active users, their monetization levels, and its FY15 revenues above the consensus through enhancements to its core app, its mobile advertising deals, and broader trends with younger people sharing content via mobile apps."
- [By James E. Brumley]
Last Friday when yours truly suggested MeetMe Inc. (NYSEMKT:MEET) shares were taking flight and were a "buy", I didn't aim to imply it was going to be the next Facebook Inc. (NASDAQ:FB) or LinkedIn Corp. (NYSE:LNKD). It was just a short-term idea assuming the near-term technical clues would get traction. Today's action from MEET seals that deal.
- [By James E. Brumley]
It took several months to get there, but shares of MeetMe Inc. (NYSEMKT:MEET) are finally living up to their potential hinted at back in July. Better still, today's bullish move from MEET isn't just some fortunate volatility. Friday's surge has taken the stock past a key line in the sand, and in so doing, has cleared the deck for more buying ahead.
Best Stocks To Own Right Now: WGL Holdings Inc (WGL)
WGL Holdings, Inc. (WGL Holdings) is a holding company. The Company own subsidiaries, which sells and delivers natural gas and/or provide a range of energy-related products and services to customers in the District of Columbia and the surrounding metropolitan areas in Maryland and Virginia. The Company operates in three subsidiaries: regulated utility segment, retail energy-marketing segment and design-build energy systems segment. The Company�� wholly owned subsidiaries include Washington Gas Light Company (Washington Gas), Washington Gas Resources Corporation (Washington Gas Resources), Hampshire Gas Company (Hampshire) and Crab Run Gas Company (Crab Run). Washington Gas is a regulated public utility that sells and delivers natural gas to customers in the District of Columbia and adjoining areas in Maryland, Virginia and several cities and towns in the northern Shenandoah Valley of Virginia. Washington Gas Resources owns four subsidiaries include Washington Gas Energy Services, Inc. (WGEServices), Washington Gas Energy Systems, Inc. (WGESystems), Capitol Energy Ventures Corp. (CEV) and WGSW, Inc. (WGSW).
Regulated Utility Segment
The Company�� regulated utility segment consists of Washington Gas and Hampshire. Washington Gas delivers natural gas to retail customers. Washington Gas also sells natural gas to customers who have not elected to purchase natural gas from un-regulated third-party marketers. Washington Gas recovers the cost of the natural gas to serve firm customers through gas cost recovery mechanisms. Hampshire operates and owns full and partial interests in underground natural gas storage facilities, including pipeline delivery facilities located in and around Hampshire County, West Virginia. Washington Gas purchases all of the storage services of Hampshire and includes the cost of these services in the bills sent to its customers.
As of September 30, 2011, Washington Gas had 1.083 million active customer meters. During the fiscal year ! ended September 30, 2011 (fiscal 2011), the Company delivered 1,772.5 million therms.
Washington Gas is responsible for acquiring sufficient natural gas supplies, interstate pipeline capacity and storage capacity. Washington Gas obtains natural gas supplies, which originate from multiple regions throughout the United States and Canada. It also obtains natural gas in the form of vaporized liquefied natural gas (LNG) through the Cove Point LNG terminal owned by Dominion Cove Point LNG, LP and Dominion Transmission, Inc. (collectively Dominion). As of September 30, 2011, Washington Gas had service agreements with four pipeline companies, which provided firm transportation and/or storage services directly to Washington Gas�� city gate.
Retail Energy-Marketing Segment
The retail energy-marketing segment consists of the operations of WGEServices, which sells the natural gas and electric commodity directly to residential, commercial and industrial customers. These commodities are delivered to retail customers through the distribution systems owned by regulated utilities, such as Washington Gas or other unaffiliated natural gas or electric utilities. Washington Gas delivers the natural gas sold by WGEServices, and unaffiliated electric utilities deliver all of the electricity sold. In addition, WGEServices bills its customers through the billing services of the regulated utilities, which deliver its commodities, as well as directly through its own billing capabilities. WGEServices owns multiple solar photovoltaic (Solar PV) power generating systems. As of September 30, 2011, WGEServices served approximately 172,000 residential, commercial and industrial natural gas customers accounts and approximately 183,000 residential, commercial and industrial electricity customers located in Maryland, Virginia, Delaware, Pennsylvania and the District of Columbia.
Design-Build Energy Systems Segment
The design-build energy systems segment, which consists ! of the op! erations of WGESystems, provides design-build energy solutions to governmental and commercial clients. WGESystems focuses on upgrading the mechanical, electrical, water and energy-related systems of governmental and commercial facilities by implementing both traditional, as well as alternative energy technologies, in the District of Columbia, Maryland and Virginia.
Other Activities
Other activities consist of the operations of CEV, an unregulated, non-utility subsidiary of Washington Gas Resources, which engages in the acquisition, management and optimization of natural gas storage and transportation assets and WGSW, which was formed to invest in solar power generation and other energy efficiency solutions for customers. In addition other activities include the operation of Crab Run, a small exploration company, and administrative with WGL Holdings and Washington Gas Resources. WGSW, a wholly owned subsidiary of Washington Gas Resources, holds a 99% partnership interest in ASD Solar, LP.
Advisors' Opinion:- [By Ali Berri]
Utilities shares surged around 0.47 percent in today’s trading. Meanwhile, top gainers in the sector included WGL Holdings (NYSE: WGL), up 5.8 percent, and American Water Works Company (NYSE: AWK), up 1.6 percent.
- [By Vanina Egea]
Looking forward, Cabot Oil and Gas reported the execution of a definitive gas sale and purchase agreement with a subsidiary of WGL Holdings (WGL), and the execution of a binding precedent agreement with Transcontinental Gas Pipe Line for a new pipeline with committed takeaway capacity from the owned asset in Susquehanna County, Pennsylvania. Most important, it holds a diversified asset portfolio spread between low-risk and long reserve-life Appalachian assets, and large-volume and rapid-payout Gulf Coast properties, with further variety from large prospect inventories in the Rocky Mountains and the Anadarko Basin that have a broad mix of production and payout profiles.
- [By Ali Berri]
Utilities shares surged around 0.87 percent in today’s trading. Meanwhile, top gainers in the sector included WGL Holdings (NYSE: WGL), up 6.3 percent, and Genie Energy (NYSE: GNE), up 2.4 percent.
- [By Lawrence Meyers]
Here are three dividend stocks that have been paying out for decades:
WGL Holdings (WGL)Dividend yield: 4.4%
Have you ever heard of WGL Holdings (WGL)? Probably not, and that’s actually a good thing. This is the kind of energy play I like because it�� highly diversified. For starters, WGL stock owns natural gas storage facilities — not the gas itself in these cases, but the storage and pipeline delivery infrastructure. Those facilities allow the company to store stuff for other people. That�� a nice margin business.
Best Stocks To Own Right Now: Telecom Italia S.P.A.(TI)
Telecom Italia S.p.A., together with its subsidiaries, provides fixed-line and mobile telecommunications, Internet, and media services. The company also operates in office and system solutions. Its portfolio ranges from consumer-focused convergent communications services to business-oriented advanced ICT solutions. The company?s integrated range of offerings, proprietary platforms, and network architecture leverage the potential of fixed-line and mobile broadband to offer convergent solutions for communication, Web surfing, always-in-touch services, and serve as a gateway to the digital world from the home, the office, and on the move, from fixed-line telephone, cell phone, PC, or TV. Its business portfolio covers various categories of business needs, from freelance professionals to SMEs, corporations, institutions, and public government bodies. The company?s Web offerings combine Italy?s Virgilio portal with Web 2.0 ventures, such as Yalp!, a TV community where users p ublish their own content and create their own TV channels. Its media operations span traditional broadcasting over analogue and digital networks, and mobile broadcasting through TIM/MTV partnership vehicle, MTV Mobile. The company has operations in Italy, Latin America, Germany, Holland, and the Mediterranean basin. As of December 31, 2009, it provided fixed telecommunications services with approximately 16.1 million physical accesses in Italy. The company?s wholesale customer portfolio consisted of approximately 6.2 million accesses for telephone services; and broadband portfolio had approximately 8.7 million accesses in Italy, as well as 30.8 million mobile telephone lines. Telecom Italia was founded in 1908 and is headquartered in Milan, Italy.
Advisors' Opinion:- [By DAILYFINANCE]
Steven Senne/AP NEW YORK -- Target (TGT) massive data breach over the holidays helped push its fourth-quarter profit down 46 percent. The discount retailer also said Wednesday that sales fell 5.3 percent as the breach scared off customers. The nation's second-largest discounter also offered a profit outlook below Wall Street expectations as the costs of the breach that affected millions of credit and debit card customers linger. The discounter, based in Minneapolis, said it earned $520 million, or 81 cents a share, for the three months that ended Feb. 1. That compares with a profit of $961 million, or $1.47 a share a year earlier. Revenue fell to $21.5 billion from $22.7 billion. Revenue at stores open at least a year, an important retail measurement, fell 2.5 percent. Analysts had expected a profit of 80 cents on revenue of 21.5 billion, according to FactSet estimates. The breach resulted in $17 million of net expenses in the fourth quarter, Target said, with $61 million of total expenses partially offset by the recognition of a $44 million insurance receivable. Shares of Target rose 99 cents to $57.50 in premarket trading Wednesday as earnings results beat Wall Street estimates by a penny. The stock has fallen about 10 percent since the company disclosed the breach in mid-December. "As we plan for the new fiscal year, we will continue to work tirelessly to win back the confidence of our guests. We are encouraged that sales trends have improved in recent weeks," Gregg Steinhafel, chairman, president and CEO of Target, said in a statement. The results underscore the big challenges that Steinhafel faces. Even before the breach, Target has struggled with uneven sales since the recession as its middle-income shoppers are still not comfortable in spending. And the company has also grappled with the perception that its prices are too high. Critics also say that the discounter, known for its exclusive limited partnerships with designers, has lost its
- [By DAILYFINANCE]
Brent Lewin/Bloomberg via Getty Images NEW YORK -- Facebook (FB) is placing a $19 billion bet on reaching its next billion mobile users with the acquisition of WhatsApp, a popular messaging service that lets people send texts, photos and videos on their smartphones. The $19 billion deal is by far Facebook's largest and bigger than any that Google (GOOG), Microsoft (MSFT) or Apple (AAPL) have ever done. But it is likely to raise worries that Facebook and other technology companies are starting to become overzealous in their pursuit of promising new products and services, said Anthony Michael Sabino, a St. John's University business professor. "This could be seen as a microcosm of a bubble," Sabino said. "I expect there to be a lot of skepticism about this deal. People are going to look at this and say, 'Uh-oh, did they pay way too much for this?" Facebook, for its part, is taking the long view. WhatsApp has 450 million monthly users, 70 percent of whom use it every day. The service is adding a million new users a day. There are 19 billion messages sent and 34 billion received via WhatsApp each day, in addition to 600 million photos and 100 million video messages. At this rate, Facebook CEO Mark Zuckerberg is confident the app will reach a billion users. Services that reach that milestone, Zuckerberg said in a statement, "are all incredibly valuable." It's an elite group to be sure -- one that includes Google (which owns YouTube), Facebook itself and little else. Facebook said Wednesday that it's paying $12 billion in stock and $4 billion in cash for WhatsApp. In addition, the app's founders and employees -- 55 in all -- will be granted restricted stock worth $3 billion that will vest over four years after the deal closes. The transaction translates to roughly 11 percent of Facebook's market value. In comparison, Google's biggest deal was its $12.5 billion purchase of Motorola Mobility, while Microsoft's largest was Skype at $8.5 billion. Apple, meanwhil
- [By Sean Williams]
Don't forget the cash flow
With austerity measures hitting home in Europe, it's fairly easy to understand why Telecom Italia (NYSE: TI ) (NYSE: TI-A ) , Italy's largest telephone service provider, has struggled mightily. Unlike in the U.S., where a landline or cell phone are viewed as practical necessities, consumers in Italy have had no problem giving up their landlines, or businesses postponing their network expansion, until Italy's economy improves. In fact, in Telecom Italia's first-quarter report, we saw EBITDA decline 10%, to $3.5 billion, and overall sales dip 8%. - [By Jon C. Ogg]
Telecom Italia SpA (NYSE: TI) was raised to Neutral from Underperform at J.P. Morgan.
Xilinx Inc. (NASDAQ: XLNX) was raised to Outperform from Sector Perform with a $55 price target (versus $a 46.54 close) at Pacific Crest.
Best Stocks To Own Right Now: EPAM Systems Inc (EPAM)
EPAM Systems, Inc. (EPAM), incorporated on December 18, 2002, is a global information technology (IT) services provider focused on software product development services, software engineering and vertically-oriented custom development solutions. EPAM has been serving independent software vendors (ISVs), and technology companies. These companies produce advanced software and technology products that demand software engineering talent, tools, methodologies and infrastructure to deliver solutions. Its service offerings cover the full software development lifecycle from complex software development services through maintenance and support, custom application development, application testing, enterprise application platforms and infrastructure management. Its key service offerings include software product development services, custom application development services, application testing services, enterprise application platforms, application maintenance and support and infrastructure management services. In December 2012, the Company acquired Empathy Lab.
Software Product Development Services
EPAM provides a set of software product development services, including product research, design and prototyping, product development, component design and integration, full lifecycle software testing, product deployment and end-user customization, performance tuning, product support and maintenance, as well as porting and cross-platform migration. The Company focuses on development services for enterprise software products covering a range of business applications, as well as product development for multiple mobile platforms and embedded software product services.
Custom Application Development Services
EPAM offers custom application development services. The Company�� range of services includes business and technical requirements analysis, solution architecture creation and validation, development, component design and integration, quality assurance and testing, d! eployment, performance tuning, support and maintenance, legacy applications re-engineering/refactoring, porting and cross-platform migration and documentation.
Application Testing Services
The Company�� application testing services include software application testing, including test automation tools and frameworks, and testing for enterprise IT, including test management, automation, functional and non-functional testing, as well as defect management. It also includes and consulting services focused on helping clients improve their existing software testing and quality assurance practices.
Enterprise Application Platforms
As a provider of software product development services to ISVs, EPAM has developed industry standard technology and business application platforms and their components in such areas as customer relationship management and sales automation, enterprise resource planning, enterprise content management, business intelligence, e-commerce, mobile, Software-as-a-Service and cloud deployment. The Company offers services around Enterprise Application Platforms, which include requirements analysis and platform selection, deep and complex customization, cross-platform migration, implementation and integration, as well as support and maintenance.
Application Maintenance and Support
EPAM delivers application maintenance and support services. The Company�� application maintenance and support offerings meet rigorous CMMI and SAS 70 Type II requirements. Its services include incident management, fault investigation diagnosis, work-around provision, application bug fixes, release management, application enhancements and third-party maintenance.
Infrastructure Management Services
EPAM service offerings cover infrastructure management services. The Company has implemented large infrastructure monitoring solutions, providing real-time notification and control from the low-level infrastructure up! to and i! ncluding applications. Its solutions cover the lifecycle of infrastructure management, including application, database, network, server, storage and systems operations management, as well as incident notification and resolution.
Advisors' Opinion:- [By Seth Jayson]
EPAM Systems (NYSE: EPAM ) reported earnings on May 9. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), EPAM Systems met expectations on revenues and missed estimates on earnings per share.
Best Stocks To Own Right Now: Mylan Inc (MYL)
Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.
As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).
Generics Segment
The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.
The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.
In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.
In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.
Specialty Segment
The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.
Advisors' Opinion:- [By George Budwell]
What might pop up as a red flag in some investors minds, however, is the company's jaw-dropping, trailing-12-month, price-to-earnings ratio of 492. After all, Teva's is a mere 17 and Mylan (NASDAQ: MYL ) comes in at 32, and those companies are Actavis' chief competitors.
Best Stocks To Own Right Now: NVIDIA Corporation(NVDA)
NVIDIA Corporation provides visual computing, high performance computing, and mobile computing solutions that generate interactive graphics on various devices ranging from tablets and smart phones to notebooks and workstations. It operates in three segments: Graphic Processing Unit (GPU), Professional Solutions Business (PSB), and Consumer Products Business (CPB). The GPU segment offers GeForce discrete and chipset products, which support desktop and notebook personal computers plus memory products. The PSB segment provides its Quadro professional workstation products and other professional graphics products, including its NVIDIA Tesla high-performance computing products used in the manufacturing, entertainment, medical, science, and aerospace industries. The CPB segment offers Tegra mobile products, which support tablets, smartphones, personal media players, Internet television, automotive navigation, and other similar devices. This segment also licenses video game consol es and other digital consumer electronics devices. The company sells its products to original equipment manufacturers, original design manufacturers, add-in-card manufacturers, consumer electronics companies, and system builders worldwide that utilize its processors as a core component of their entertainment, business, and professional solutions. NVIDIA Corporation was founded in 1993 and is headquartered in Santa Clara, California.
Advisors' Opinion:- [By Mani]
NVIDIA Corporation (NASDAQ: NVDA) plans to release its third quarter financial results on�Nov.7. The graphics chip maker company will host a conference call on the same day at�2 p.m. PT�(5 p.m. ET) to discuss the operating performance for the third quarter.
No comments:
Post a Comment